

CLAIMS

1. 10-Propargyl-10-deazaaminopterin, substantially free of 10-deazaaminopterin.
2. A composition consisting essentially of 10-Propargyl-10-deazaaminopterin.
3. A pharmaceutical composition comprising 10-Propargyl-10-deazaaminopterin, substantially free of 10-deazaaminopterin, and a pharmaceutically acceptable carrier.
4. A method for treatment of tumors comprising administering to a human patient diagnosed as having a tumor a therapeutically effective amount of 10-propargyl-10-deazaaminopterin, substantially free of 10-deazaaminopterin.
5. The method according to claim 4, wherein the tumor is a solid tumor.
6. The method according to claim 4, wherein the 10-propargyl-10-deazaaminopterin, substantially free of 10-deazaaminopterin, is administered in amounts of from 40 to 120 mg/m² of body surface area/day.
7. The method according to claim 5, wherein the tumor is a mammary tumor.
8. The method according to claim 4, wherein the tumor is a lung tumor.

106 Rec'd PCT/PTO 10 FEB 1998

1 9. The pharmaceutical composition according to claim 3, further
2 comprising at least one additional cytotoxic or antitumor compound.

1 10. The pharmaceutical composition according to claim 9, wherein
2 the at least one additional cytotoxic or antitumor compound is selected from the group
3 consisting of vinca alkaloids, 5-fluorouracil, alkylating agents, cisplatin, carboplatin,
4 leucovorin, taxols and antibiotics.

1 11. The method according to claim 4, wherein at least one
2 additional cytotoxic or antitumor compound is administered with the therapeutically
3 effective amount of 10-propargyl-1-deazaaminopterin, substantially free of 10-
4 deazaaminopterin.

1 12. The method according to claim 11, wherein the at least one
2 additional cytotoxic or antitumor compound is selected from the group consisting of
3 vinca alkaloids, 5-fluorouracil, alkylating agents, cisplatin, carboplatin, leucovorin,
4 taxols and antibiotics.

AMENDED SHEET
K